Ovarian cancer vaccine shows promise in small safety trial
NCT ID NCT02111941
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This study tested a custom-made vaccine for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine was made from each patient's own white blood cells and designed to train the immune system to attack cancer cells. The main goal was to see if the vaccine was safe, and it involved 19 participants who had already completed surgery and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SEROMUCINOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.